Amy Axel

3.1k total citations · 2 hit papers
29 papers, 2.3k citations indexed

About

Amy Axel is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Amy Axel has authored 29 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 15 papers in Oncology and 10 papers in Genetics. Recurrent topics in Amy Axel's work include Multiple Myeloma Research and Treatments (14 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Amy Axel is often cited by papers focused on Multiple Myeloma Research and Treatments (14 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Amy Axel collaborates with scholars based in United States, Netherlands and Belgium. Amy Axel's co-authors include A. Kate Sasser, Brett M. Hall, Nicholas J. Sullivan, Tatiana M. Oberyszyn, Venu Raman, Farhad Vesuna, Nilsa C. Ramirez, Niels W.C.J. van de Donk, Henk M. Lokhorst and Adam Studebaker and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Amy Axel

28 papers receiving 2.2k citations

Hit Papers

Interleukin-6 induces an epithelial–mesenchymal transitio... 2009 2026 2014 2020 2009 2016 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells
    2009 605 citations Nicholas J. Sullivan, A. Kate Sasser et al. Oncogene profile →
  2. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
    2016 303 citations Saad Z. Usmani, Brendan M. Weiss et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy Axel United States 17 1.4k 944 892 530 379 29 2.3k
Kodandaram Pillarisetti United States 19 1.1k 0.8× 670 0.7× 748 0.8× 641 1.2× 372 1.0× 37 2.0k
Michael Hundemer Germany 27 719 0.5× 1.0k 1.1× 954 1.1× 565 1.1× 100 0.3× 87 1.9k
Thomas Kindler Germany 27 615 0.4× 1.7k 1.8× 1.5k 1.6× 342 0.6× 139 0.4× 78 3.0k
Patricia Maiso United States 24 810 0.6× 1.3k 1.3× 2.0k 2.2× 600 1.1× 84 0.2× 64 3.1k
M. S. Berger United States 19 948 0.7× 469 0.5× 857 1.0× 342 0.6× 373 1.0× 37 2.1k
Güllü Görgün United States 31 1.4k 1.0× 1.5k 1.5× 1.7k 1.9× 1.4k 2.6× 134 0.4× 74 3.8k
Keiko Okuda Japan 24 651 0.5× 1.2k 1.3× 949 1.1× 717 1.4× 115 0.3× 67 2.6k
Robert L. Cohen United States 14 528 0.4× 403 0.4× 1.2k 1.4× 449 0.8× 151 0.4× 23 2.2k
Els Van Valckenborgh Belgium 36 1.1k 0.8× 1.3k 1.4× 1.8k 2.0× 610 1.2× 53 0.1× 77 2.9k
Michaël Sébag Canada 23 766 0.6× 801 0.8× 1.0k 1.2× 187 0.4× 255 0.7× 115 1.8k

Countries citing papers authored by Amy Axel

Since Specialization
Citations

This map shows the geographic impact of Amy Axel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Axel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Axel more than expected).

Fields of papers citing papers by Amy Axel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Axel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Axel. The network helps show where Amy Axel may publish in the future.

Co-authorship network of co-authors of Amy Axel

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Axel. A scholar is included among the top collaborators of Amy Axel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Axel. Amy Axel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Belch, Andrew, Torben Plesner, Paul G. Richardson, et al.. (2024). Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Carolina Digital Repository (University of North Carolina at Chapel Hill).
2.
Hall, Brett M., Anna Travesa, Amy Axel, et al.. (2022). 449 Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the dual MEK inhibitor, IMM-6-415, enhances PD1 and CTLA4 checkpoint blockade in RAS mutant tumors. Regular and Young Investigator Award Abstracts. A469–A469. 2 indexed citations
3.
Verkleij, Christie P.M., Marloes E.C. Broekmans, Mark van Duin, et al.. (2021). Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Advances. 5(8). 2196–2215. 117 indexed citations
4.
King, Peter, Amy Axel, Kevin Fowler, et al.. (2021). Abstract P240: Benchmarking the novel dual-MEK inhibitor, IMM-1-104, head-to-head and in combination with sotorasib (AMG-510) in the MIA PaCa-2 (KRAS-G12C) pancreatic cancer xenograft model. Molecular Cancer Therapeutics. 20(12_Supplement). P240–P240. 1 indexed citations
5.
Frerichs, Kristine A., Marloes E.C. Broekmans, Berris van Kessel, et al.. (2020). Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab. Clinical Cancer Research. 26(9). 2203–2215. 68 indexed citations
6.
Verkleij, Christie P.M., Marloes E.C. Broekmans, Mark van Duin, et al.. (2019). Preclinical evaluation of the new GPRC5DxCD3 (JNJ-7564) bispecific antibody for the treatment of multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 19(10). e122–e123. 5 indexed citations
7.
Cole, Suzanne, Alice M. Walsh, Xuefeng Yin, et al.. (2018). Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus. Arthritis Research & Therapy. 20(1). 85–85. 85 indexed citations
8.
Casneuf, Tineke, Xu Steven Xu, Homer Adams, et al.. (2017). Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Advances. 1(23). 2105–2114. 160 indexed citations
9.
Nijhof, Inger S., Tineke Casneuf, Berris van Kessel, et al.. (2016). CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 128(7). 959–970. 275 indexed citations
10.
Sasser, Kate, Tineke Casneuf, Amy Axel, et al.. (2016). Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer. Breast Cancer Targets and Therapy. 8. 13–13. 20 indexed citations
11.
Casneuf, Tineke, Xiuping Xu, Amy Axel, et al.. (2016). PHARMACODYNAMIC RELATIONSHIP BETWEEN NATURAL KILLER CELLS AND DARATUMUMAB EXPOSURE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA. Pure Amsterdam UMC. 101. 87–88. 7 indexed citations
12.
Usmani, Saad Z., Brendan M. Weiss, Torben Plesner, et al.. (2016). Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 128(1). 37–44. 303 indexed citations breakdown →
13.
Caillon, Hélène, Jason S. Simon, Amy Axel, et al.. (2016). Overcoming the Interference of Daratumumab with Immunofixation Electrophoresis (IFE) Using an Industry-Developed Dira Test : Hydrashift 2/4 Daratumumab. Blood. 128(22). 2063–2063. 14 indexed citations
14.
Usmani, Saad Z., Brendan M. Weiss, Nizar J. Bahlis, et al.. (2015). Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma. Blood. 126(23). 29–29. 12 indexed citations
15.
McCudden, Christopher R., Amy Axel, Dominique Slaets, et al.. (2015). Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): Validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody.. Journal of Clinical Oncology. 33(15_suppl). 8590–8590. 16 indexed citations
16.
Syed, Khaja, et al.. (2015). Preclinical Evaluation of CSL362/JNJ-56022473 in Combination with Decitabine or Azacitidine in in Vitro Assays. Blood. 126(23). 1370–1370. 7 indexed citations
17.
Krausz, Eberhard, Ronald De Hoogt, Emmanuel Gustin, et al.. (2012). Translation of a Tumor Microenvironment Mimicking 3D Tumor Growth Co-culture Assay Platform to High-Content Screening. SLAS DISCOVERY. 18(1). 54–66. 52 indexed citations
18.
Sullivan, Nicholas J., A. Kate Sasser, Amy Axel, et al.. (2009). Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells. Oncogene. 28(33). 2940–2947. 605 indexed citations breakdown →
19.
Lagmay, Joanne, Wendy B. London, Thomas G. Gross, et al.. (2009). Prognostic Significance of Interleukin-6 Single Nucleotide Polymorphism Genotypes in Neuroblastoma:rs1800795(Promoter) andrs8192284(Receptor). Clinical Cancer Research. 15(16). 5234–5239. 36 indexed citations
20.
Sasser, A. Kate, Bethany L. Mundy-Bosse, Kristen M. Smith, et al.. (2007). Human bone marrow stromal cells enhance breast cancer cell growth rates in a cell line-dependent manner when evaluated in 3D tumor environments. Cancer Letters. 254(2). 255–264. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kodandaram Pillarisetti Breakdown of academic impact, for papers by Michael Hundemer Breakdown of academic impact, for papers by Thomas Kindler Breakdown of academic impact, for papers by Patricia Maiso Breakdown of academic impact, for papers by M. S. Berger Breakdown of academic impact, for papers by Güllü Görgün Breakdown of academic impact, for papers by Keiko Okuda Breakdown of academic impact, for papers by Robert L. Cohen Breakdown of academic impact, for papers by Els Van Valckenborgh Breakdown of academic impact, for papers by Michaël Sébag
Rankless by CCL
2026